GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nextage Therapeutics Ltd (XTAE:NXTG) » Definitions » Additional Paid-In Capital

Nextage Therapeutics (XTAE:NXTG) Additional Paid-In Capital : ₪1.43 Mil(As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Nextage Therapeutics Additional Paid-In Capital?


Nextage Therapeutics's quarterly additional paid-in capital declined from Dec. 2022 (₪4.53 Mil) to Jun. 2023 (₪2.67 Mil) but then stayed the same from Jun. 2023 (₪2.67 Mil) to Dec. 2023 (₪1.43 Mil).

Nextage Therapeutics's annual additional paid-in capital increased from Dec. 2021 (₪0.00 Mil) to Dec. 2022 (₪4.53 Mil) but then declined from Dec. 2022 (₪4.53 Mil) to Dec. 2023 (₪1.43 Mil).


Nextage Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Nextage Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nextage Therapeutics Additional Paid-In Capital Chart

Nextage Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial - - - 4.53 1.43

Nextage Therapeutics Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 4.53 2.67 1.43

Nextage Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Nextage Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Nextage Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Nextage Therapeutics (XTAE:NXTG) Business Description

Traded in Other Exchanges
N/A
Address
Bio-Light, Kiryat Atidim 7, Entrance 1, 2rd Floor, Tel Aviv, ISR, 61581
Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.

Nextage Therapeutics (XTAE:NXTG) Headlines